Andrea Corcoran Biography and Net Worth

Insider of Atea Pharmaceuticals

Andrea brings more than 20 years’ experience in the biopharmaceutical industry to Atea’s management team.

Prior to joining Atea, Andrea served as Senior Vice President, Strategy and Finance at iBio from 2011 to 2012, General Counsel and Secretary of Tolerx from 2007 to 2011 and Executive Vice President of Idenix Pharmaceuticals from 1998 to 2007.

Earlier in her career, Andrea worked with the law firms Kelley Drye & Warren LLP and Edwards & Angell LLP (now Locke Lorde), and in the assurance practice of PricewaterhouseCoopers as a certified public accountant.

Andrea holds a BS in Accounting from Providence College and a JD from Boston College Law School.

What is Andrea Corcoran's net worth?: The estimated net worth of Andrea Corcoran is at least $2.07 million as of February 1st, 2024. Corcoran owns 670,208 shares of Atea Pharmaceuticals stock worth more than $2,070,943 as of December 5th. This net worth estimate does not reflect any other investments that Corcoran may own. Additionally, Corcoran receives an annual salary of $712,480.00 as Insider at Atea Pharmaceuticals. Learn More about Andrea Corcoran's net worth.
How old is Andrea Corcoran?: Corcoran is currently 62 years old. There are 5 older executives and no younger executives at Atea Pharmaceuticals. The oldest executive at Atea Pharmaceuticals is Dr. Jean-Pierre Sommadossi Ph.D., Founder, Chairman, CEO & President, who is 68 years old. Learn More on Andrea Corcoran's age.
What is Andrea Corcoran's salary?: As the Insider of Atea Pharmaceuticals, Inc., Corcoran earns $712,480.00 per year. There are 2 executives that earn more than Corcoran. The highest earning executive at Atea Pharmaceuticals is Dr. Jean-Pierre Sommadossi Ph.D., Founder, Chairman, CEO & President, who commands a salary of $1,040,000.00 per year. Learn More on Andrea Corcoran's salary.
How do I contact Andrea Corcoran?: The corporate mailing address for Corcoran and other Atea Pharmaceuticals executives is , , . Atea Pharmaceuticals can also be reached via phone at 857-284-8891 and via email at [email protected]. Learn More on Andrea Corcoran's contact information.
Has Andrea Corcoran been buying or selling shares of Atea Pharmaceuticals?: Andrea Corcoran has not been actively trading shares of Atea Pharmaceuticals in the last ninety days. Most recently, Andrea Corcoran sold 15,843 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $3.84, for a transaction totalling $60,837.12. Following the completion of the sale, the insider now directly owns 670,208 shares of the company's stock, valued at $2,573,598.72. Learn More on Andrea Corcoran's trading history.
Who are Atea Pharmaceuticals' active insiders?: Atea Pharmaceuticals' insider roster includes Franklin Berger (Director), Andrea Corcoran (Insider), Wayne Foster (CAO), Polly Murphy (Director), Bruce Polsky (Director), and Jean-Pierre Sommadossi (CEO). Learn More on Atea Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Atea Pharmaceuticals?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 359,606 shares worth more than $1,024,877.10. The most recent insider tranaction occured on December, 10th when Director Franklin M Berger sold 359,606 shares worth more than $1,024,877.10. Insiders at Atea Pharmaceuticals own 18.1% of the company. Learn More about insider trades at Atea Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Andrea Corcoran Insider Trading History at Atea Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/1/2024	Sell	15,843	$3.84	$60,837.12	670,208

Andrea Corcoran Buying and Selling Activity at Atea Pharmaceuticals

Atea Pharmaceuticals Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $3.09

$3.03

$3.13

50 Day Range

MA: $3.12

$2.82

$3.50

2 Week Range

Now: $3.09

$2.45

$4.02

Volume

497,950 shs

Average Volume

411,257 shs

Market Capitalization

$241.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Andrea Corcoran Biography and Net Worth

What is Andrea Corcoran's net worth?

How old is Andrea Corcoran?

What is Andrea Corcoran's salary?

How do I contact Andrea Corcoran?

Has Andrea Corcoran been buying or selling shares of Atea Pharmaceuticals?

Who are Atea Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Atea Pharmaceuticals?